TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 1.20nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 2nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 2nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 3nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 3.40nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 8nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 8nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 8nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 10nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 42nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 1.26E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 1.34E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 2.81E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 4.56E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 6.37E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: 7.54E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: >1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: >1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: >1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: >1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Aska Pharmaceutical
US Patent
Aska Pharmaceutical
US Patent
Affinity DataIC50: >1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair